ACE2对乳腺癌预后的影响及其潜在机制

徐灵亚; 刘雪; 曹潇洋; 张馨怡; 姚静; 王传功

doi:10.11665/j.issn.1000-5048.2023033102

ACE2对乳腺癌预后的影响及其潜在机制

1.
潍坊医学院基础医学院，潍坊 261053
2.
济宁医学院基础医学院，济宁 272067

基金项目: 国家自然科学基金资助项目（No.81902518）

计量
- 文章访问数: 139
- HTML全文浏览量: 5
- PDF下载量: 260
出版历程
- 收稿日期: 2023-03-30
- 修回日期: 2023-09-04
- 刊出日期: 2023-10-24

Effect of ACE2 on the prognosis of breast cancer and its potential mechanism

1.
School of Basic Medicine, Weifang Medical University, Weifang 261053
2.
School of Basic Medical, Jining Medical University, Jining 272067, China

Funds: This study was supported by the National Natural Science Foundation of China (No.81902518)

摘要

摘要: 研究跨膜蛋白血管紧张素转换酶2（angiotensin converting enzyme 2，ACE2）对乳腺癌预后的影响及其潜在机制。使用公共数据库分析ACE2表达和与乳腺癌患者临床病理特征、患者预后及免疫微环境的关系；结合体外实验分析ACE2在乳腺癌中的作用机制。研究结果显示，ACE2在乳腺癌组织中的表达明显低于乳腺正常组织，其表达与乳腺癌患者的年龄、M分期和N1mi期显著负相关（P < 0.05）。ACE2高表达的Luminal型乳腺癌患者预后不良，而在三阴性乳腺癌（triple-negative breast cancer，TNBC）亚型中，ACE2则展现出不同的预后意义。此外，ACE2还与肿瘤组织的代谢和免疫微环境密切相关。体外实验表明，ACE2在MDA-MB-231细胞中低表达，并可能通过下调基质金属蛋白酶2（MMP2）来抑制细胞的进展。研究结果提示，ACE2在乳腺癌中低表达，与患者的预后及代谢和免疫微环境密切相关，其可能是通过MMP2途径抑制TNBC细胞进展。
- 乳腺肿瘤 /
- 血管紧张素转换酶2 /
- 三阴性乳腺癌 /
- 基质金属蛋白酶2
Abstract: This study aims to investigate the effect of transmembrane protein angiotensin converting enzyme 2 (ACE2) on the prognosis of breast cancer and its potential mechanism.Public databases were used to analyze ACE2 expression and its relationship with clinicopathological features and prognosis of breast cancer patients, combined with in vitro experiments to analyze the mechanism of action and immune relevance of ACE2 in breast cancer.Results showed that the expression of ACE2 in breast cancer tissues was significantly lower than that in normal breast tissues, and that its expression was negatively correlated with age, M stage and N1mi stage of breast cancer patients (P < 0.05).Patients with Luminal type breast cancer with high ACE2 expression had poor prognosis, while in the triple-negative breast cancer (TNBC) subtype, ACE2 showed different prognostic significance.In addition, ACE2 is closely associated with the metabolic and immune microenvironment of tumor tissue.In vitro experiments have shown that ACE2 is lowly expressed in MDA-MB-231 cells and may inhibit cell progress by downregulating matrix metalloproteinase 2（MMP2）.The results suggest that the low expression of ACE2 in breast cancer is closely associated with patient prognosis as well as metabolic and immune microenvironment, and that ACE2 may inhibit TNBC cell progress through the MMP2 pathway.
- breast cancer /
- angiotensin converting enzyme 2 /
- triple-negative breast cancer /
- matrix metalloproteinase 2

HTML全文

参考文献(23)

[1]	Kocarnik JM, Compton K, Dean FE, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019[J]. JAMA Oncol, 2022, 8(3): 420-444.
[2]	Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48.
[3]	Liu X, Li YQ, Mu FC, et al. New progress in molecular typing of triple negative breast cancer[J]. Chin J Clin Exp Pathol (临床与实验病理学杂志), 2020, 36(3): 316-319.
[4]	Waks AG, Winer EP. Breast cancer treatment: a review[J]. JAMA, 2019, 321(3): 288-300.
[5]	Wang X, Wang SS, Huang H, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial[J]. JAMA, 2021, 325(1): 50-58.
[6]	Arendse LB, Jan Danser AHJ, Poglitsch M, et al. Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure[J]. Pharmacol Rev, 2019, 71(4): 539-570.
[7]	Savoia C, Volpe M, Kreutz R. Hypertension, a moving target in COVID-19: current views and perspectives[J]. Circ Res, 2021, 128(7): 1062-1079.
[8]	RASSantos, Sampaio WO, Alzamora AC, et al. The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7)[J]. Physiol Rev, 2018, 98(1): 505-553.
[9]	Liu FF, Gong ZK, Liang HL, et al. Progress of the relationship between renin-angiotensin system and tumor[J]. J Mod Oncol (现代肿瘤医学), 2022, 30(8): 1495-1499.
[10]	Acconcia F. The network of angiotensin receptors in breast cancer[J]. Cells, 2020, 9(6): 1336.
[11]	Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation[J]. Nature, 2012, 487(7408): 477-481.
[12]	Viana SD, Nunes S, Reis F. ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities - Role of gut microbiota dysbiosis[J]. Ageing Res Rev, 2020, 62: 101123.
[13]	Li ZL, Peng MX, Chen P, et al. Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry[J]. Cell Metab, 2022, 34(3): 424-440.
[14]	Yu CH, Tang W, Wang YH, et al. Downregulation of ACE2/Ang-(1-7)/Mas axis promotes breast cancer metastasis by enhancing store-operated calcium entry[J]. Cancer Lett, 2016, 376(2): 268-277.
[15]	Ye GX, Qin Y, Lu XH, et al. The association of renin-angiotensin system genes with the progression of hepatocellular carcinoma[J]. Biochem Biophys Res Commun, 2015, 459(1): 18-23.
[16]	Khanna P, Soh HJ, Chen CH, et al. ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma[J]. Sci Transl Med, 2021, 13(577): eabc0170.
[17]	Zhang Q, Lu SH, Li TF, et al. ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway[J]. J Exp Clin Cancer Res, 2019, 38(1): 173.
[18]	Zhang SB, Zhao BB, Gao H, et al. Dexmedetomidine mediated miR-526b-3p/MMP2 pathway affects the invasion and migration of human cervical cancer cell line HeLa[J]. Chin J Birth Heath Hered (中国优生与遗传杂志), 2022, 30(10): 1703-1708.
[19]	Jackson CB, Farzan M, Chen B, et al. Mechanisms of SARS-CoV-2 entry into cells[J]. Nat Rev Mol Cell Biol, 2022, 23(1): 3-20.
[20]	Brown JM, Wasson MD, Marcato P. Triple-negative breast cancer and the COVID-19 pandemic: clinical management perspectives and potential consequences of infection[J]. Cancers, 2021, 13(2): 296.
[21]	Xiao Y, Ma D, Yang YS, et al. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer[J]. Cell Res, 2022, 32(5): 477-490.
[22]	Niland S, Riscanevo AX, Eble JA. Matrix metalloproteinases shape the tumor microenvironment in cancer progression[J]. Int J Mol Sci, 2021, 23(1): 146.
[23]	Sanyal S, Amin SA, Adhikari N, et al. Ligand-based design of anticancer MMP2 inhibitors: a review[J]. Future Med Chem, 2021, 13(22): 1987-2013.

施引文献

资源附件(0)

计量

文章访问数: 139
HTML全文浏览量: 5
PDF下载量: 260
被引次数: 0

ACE2对乳腺癌预后的影响及其潜在机制

计量

出版历程

Effect of ACE2 on the prognosis of breast cancer and its potential mechanism

计量

出版历程

目录